Share Email Print

Proceedings Paper • new

NIR-triggered photodynamic therapy via antigen-capturing upconversion nanoparticle enhances cancer immunotherapy (Conference Presentation)
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

NIR-triggered photodynamic therapy via antigen-capturing upconversion nanoparticle enhances cancer immunotherapy Meng Wang,a,b Lu Wang,a Benqing, Zhou,a,b Feifan Zhou,b Wei R. Chen*a a Biophotonics Research Laboratory, Center of Interdisciplinary Biomedical Education and Research, College of Mathematics and Science, University of Central Oklahoma, Oklahoma, 73034, USA b Key Laboratory of Optoelectronic Devices and Systems of Ministry of Education and Guangdong Province, College of Optoelectronic Engineering, Shenzhen University, Shenzhen, 518060, P. R. China Abstract Photodynamic therapy (PDT) as a promising cancer treatment strategy has the ability to induce antitumor immune responses. However, conventional PDT using photosensitizers activated by visible light has limited penetration depth, which attenuates severely the effectiveness of induced immune responses. We developed an NIR-triggered antigen-capturing nano-photosensitizer, using upconversion nanoparticles (NPs), indocyanine green (ICG), Rose Bangel (RB), a photosensitizer, and maleimides (mal) for cancer treatment. NP/ICG/RB-mal can be used not only for photodynamic therapy, but also for cancer immunotherapy though in situ tumor-associated antigens capturing. With ICG, NP/ICG/RB-mal increases the UCNP emission intensity to achieve higher PDT efficiency and, at the same time, enhances photothermal therapy (PTT). Tumor-associated antigens arising from the PDT/PTT can further be captured by NP/ICG/RB-mal in situ, and delivered to antigen-presenting cells (APCs) to induce a tumor-specific immune response. As a result, a remarkable in vivo synergistic therapeutic effect is achieved using NP/ICG/RB-mal under laser irradiation in treating metastatic tumors.

Paper Details

Date Published: 7 March 2019
Proc. SPIE 10879, Biophotonics and Immune Responses XIV, 1087905 (7 March 2019); doi: 10.1117/12.2507021
Show Author Affiliations
Meng Wang, Shenzhen Univ. (China)
Lu Wang, Univ. of Central Oklahoma (United States)
Benqing Zhou, Shenzhen Univ. (China)
Feifan Zhou, Shenzhen Univ. (China)
Wei Chen, Univ. of Central Oklahoma (United States)

Published in SPIE Proceedings Vol. 10879:
Biophotonics and Immune Responses XIV
Wei R. Chen, Editor(s)

© SPIE. Terms of Use
Back to Top